Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 4/20 | 0.64 |
| ▸ | ORAI1 | Q96D31 | 4/20 | 0.64 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | IL2 | P60568 | 8/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16020543 | 0.91 | STIM1 (0.54) | STIM1ORAI1ORAI2RXFP1IL2 | |
| SCHEMBL14881300 | 0.89 | STIM1 (0.68) | STIM1ORAI1ORAI2IL2EPAS1 | |
| SCHEMBL14885665 | 0.87 | STIM1 (0.50) | STIM1ORAI1ORAI2RXFP1IL2 | |
| SCHEMBL16020568 | 0.85 | STIM1 (0.64) | STIM1ORAI1ORAI2IL2TDP1 | |
| SCHEMBL14885683 | 0.85 | STIM1 (0.64) | STIM1ORAI1ORAI2IL2TDP1 | |
| SCHEMBL16020570 | 0.82 | STIM1 (0.59) | STIM1ORAI1ORAI2IL2HDAC4 | |
| SCHEMBL14887769 | 0.81 | STIM1 (0.43) | STIM1ORAI1ORAI2RXFP1IL2 | |
| SCHEMBL16018200 | 0.80 | STIM1 (0.64) | STIM1ORAI1ORAI2IL2EPAS1 | |
| SCHEMBL14885682 | 0.80 | STIM1 (0.64) | STIM1ORAI1ORAI2GAATDP1 | |
| SCHEMBL16018198 | 0.79 | STIM1 (0.70) | STIM1ORAI1ORAI2IL2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256745-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256745-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.